Quality of medical products for diabetes management: a systematic review
暂无分享,去创建一个
[1] Medicines And Healthcare Products Regulatory Agency , 2020, Definitions.
[2] S. Ozawa,et al. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries , 2018, JAMA network open.
[3] P. Srinivas,et al. Perceptions of the quality of generic medicines: implications for trust in public services within the local health system in Tumkur, India , 2018, BMJ Global Health.
[4] É. Marijon,et al. Fighting fake medicines: First quality evaluation of cardiac drugs in Africa. , 2017, International journal of cardiology.
[5] N. Alam,et al. A comparative in vitro dissolution of different brands of glibenclamide tablets available in Saudi Arabian market , 2017 .
[6] Hazhar Karim,et al. IN VITRO EQUIVALENCE EVALUATION OF FIVE DIFFERENT METFORMIN TABLET PRODUCTS USING UV SPECTROMETER , 2016 .
[7] D. Moore,et al. The global diabetes epidemic: what does it mean for infectious diseases in tropical countries? , 2016, The Lancet Diabetes & Endocrinology.
[8] F. Sakr,et al. Evaluation of the quality and pharmacoeconomics of some generic drugs versus their reputed counterpart brands in the Saudi market , 2016 .
[9] Patricia Courselle,et al. A simple dilute and shoot methodology for the identification and quantification of illegal insulin☆ , 2016, Journal of pharmaceutical analysis.
[10] Gretchen A. Stevens,et al. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants , 2016, Lancet.
[11] D. Beran,et al. Constraints and challenges in access to insulin: a global perspective. , 2016, The lancet. Diabetes & endocrinology.
[12] C. Gedeon,et al. Counterfeit diabetes products and the ethical question of access , 2015 .
[13] K. Aryal,et al. Surveillance of Quality of Medicines Available in the Nepalese Market: A Study from Kathmandu Valley. , 2015, Journal of Nepal Health Research Council.
[14] P. Newton,et al. Responding to the Pandemic of Falsified Medicines , 2015, The American journal of tropical medicine and hygiene.
[15] Matthew E. Falagas,et al. Substandard/Counterfeit Antimicrobial Drugs , 2015, Clinical Microbiology Reviews.
[16] C. Ebenezer. Pharmaceutical quality and policy in Nigeria : stakeholder perspectives and validation of the Mobile Authentication Service , 2015 .
[17] Bernadette A. Thomas,et al. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.
[18] S. Haidar,et al. PHARMACEUTICAL QUALITY OF GENERIC SITAGLIPTIN TABLETS COMPARED WITH JANUVIA , 2014 .
[19] E. Redwan,et al. Cell factories for insulin production , 2014, Microbial Cell Factories.
[20] F. Schifano,et al. A systematic review of counterfeit and substandard medicines in field quality surveys , 2014 .
[21] Patricia Tabernero,et al. Mind the gaps - the epidemiology of poor-quality anti-malarials in the malarious world - analysis of the WorldWide Antimalarial Resistance Network database , 2014, Malaria Journal.
[22] Tatiana Dilla,et al. Adherence to Therapies in Patients with Type 2 Diabetes , 2013, Diabetes Therapy.
[23] O. Oyetunde,et al. In Vitro Equivalence Studies of Generic Metformin Hydrochloride Tablets and Propranolol Hydrochloride Tablets Under Biowaiver Conditions in Lagos State, Nigeria , 2012 .
[24] P. Newton,et al. How to achieve international action on falsified and substandard medicines , 2012, BMJ : British Medical Journal.
[25] I. Adelaja,et al. Comparative Evaluation of Physicochemical Properties of Some Commercially Available Brands of Metformin Hcl Tablets in Lagos, Nigeria , 2012 .
[26] Won Chan Lee,et al. Cost of Self-Monitoring of Blood Glucose in the United States Among Patients on an Insulin Regimen for Diabetes , 2012, Journal of managed care pharmacy : JMCP.
[27] P. Newton,et al. The Primacy of Public Health Considerations in Defining Poor Quality Medicines , 2011, PLoS Medicine.
[28] Raffaella Ravinetto,et al. Quality of medical devices and in vitro diagnostics in resource‐limited settings , 2011, Tropical medicine & international health : TM & IH.
[29] I. Hamdan,et al. Pharmaceutical Evaluation of Metformin HCl Products Available in the Jordanian Market , 2010 .
[30] J. Rodríguez,et al. Los medicamentos falsificados en Perú , 2010 .
[31] Jan S Krouwer,et al. A Review of Standards and Statistics Used to Describe Blood Glucose Monitor Performance , 2010, Journal of diabetes science and technology.
[32] S. Kao,et al. An unusual outbreak of hypoglycemia. , 2009, The New England journal of medicine.
[33] M. M. Cheng. Is the Drugstore Safe? Counterfeit Diabetes Products on the Shelves , 2009, Journal of diabetes science and technology.
[34] D. Moher,et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.
[35] P. Newton,et al. Guidelines for Field Surveys of the Quality of Medicines: A Proposal , 2009, PLoS medicine.
[36] M. Massi-Benedetti,et al. Quality and behavior of glimepiride generics versus amaryl under stressed conditions. , 2007, Diabetes technology & therapeutics.
[37] Paul N Newton,et al. Counterfeit anti-infective drugs. , 2006, The Lancet. Infectious diseases.
[38] Alastair Gray,et al. Economic burden of cardiovascular diseases in the enlarged European Union. , 2006, European heart journal.
[39] J. Concato,et al. Long-term glycemic control and postoperative infectious complications. , 2006, Archives of surgery.
[40] L. Buhse,et al. Quality assessment of internet pharmaceutical products using traditional and non-traditional analytical techniques. , 2005, International journal of pharmaceutics.
[41] P. Newton,et al. The Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate the Dangers , 2005, PLoS medicine.
[42] A. Holstein,et al. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. , 2003, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[43] J. Scarpello. Review: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes: , 2001 .
[44] R. Holman,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.
[45] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[46] A. Garber,et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. , 1997, The American journal of medicine.
[47] FDA News , 1995 .
[48] L. Groop. Sulfonylureas in NIDDM , 1992, Diabetes Care.
[49] M. Blaser,et al. Campylobacter serology in patients with Chinese paralytic syndrome , 1991, The Lancet.
[50] P. Wise,et al. Detection of glibenclamide in oral insulin capsules , 1991, The Lancet.
[51] T. Adrian,et al. AUTOIMMUNITY IN DIABETICS INDUCED BY HORMONAL CONTAMINANTS OF INSULIN , 1979, The Lancet.
[52] I. Leopold. Editorial: Consolidation of United States Pharmacopeia and National Formulary. , 1974, American journal of ophthalmology.
[53] A. Hirschfelder. THE UNITED STATES PHARMACOPEIAL CONVENTION , 1930 .
[54] A. Mitra. Diabetes , 1894, The Indian medical gazette.
[55] H. Fukuda,et al. Impact of nonadherence on complication risks and healthcare costs in patients newly-diagnosed with diabetes. , 2017, Diabetes research and clinical practice.
[56] M. Iwuagwu,et al. A comparative evaluation of the pharmaceutical quality of different brands of metformin hydrochloride tablets available in Abuja , Nigeria , 2017 .
[57] Vineet Kumar,et al. Comparative in-vitro evaluation of four different brands of metformin HClavailable in Kanpur district, India , 2016 .
[58] M. M. Gupta,et al. In-vitro Pharmaceutical Quality Control Testing: a Comparative study of Different Brands of Metformin Tablets Available in the Trinidad & Tobago, West Indies , 2016 .
[59] T. Ajala,et al. The Pharmaceutical Quality of Brands of Metformin Tablets in Ogun-State, Nigeria , 2014 .
[60] J. Bergquist,et al. Pharmaceutical Evaluation of Type II Oral Antidiabetic Agent , 2014 .
[61] Ramesh,et al. A Comparative Analysis of Commercial Metformin Tablets. , 2014 .
[62] P. Debnath,et al. Analytical appraisement of some commercially available brands of Metformin Hydrochloride Tablet in Dhaka, Bangladesh , 2013 .
[63] Dear Mr,et al. Inspections, Compliance, Enforcement, and Criminal Investigations , 2012 .
[64] S. Afifi,et al. for Evaluation of Different Brands of Metformin Hydrochloride 500 Mg Tablets Marketed in Saudi Arabia , 2012 .
[65] S. Muralidharan,et al. Invitro studies and evaluation of metformin marketed tablets-Malaysia , 2011 .
[66] J. Firth,et al. Comprar Oxford Textbook of Medicine 5Ed | Edward J. Benz | 9780199204854 | Oxford University Press , 2010 .
[67] Inspections , Compliance , Enforcement , and Criminal Investigations , 2009 .
[68] James Ahlquist. Oxford Textbook of Medicine , 1997, Journal of the Royal College of Physicians of London.
[69] H. Blume,et al. Pharmaceutical Quality of Glibenclamide Products A Multinational Postmarket Comparative Study , 1993 .
[70] S. Lande. Oxford Textbook of Medicine , 1983, The Yale Journal of Biology and Medicine.
[71] G WhittakerP,et al. 共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値 , 1980 .